https://www.biopharmawatch.com/news/MIRM/mirum-investor-call-phase-3-expand-study-livmarli BiopharmaWatch en 2026-10-11T21:00:00.000Z Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases https://www.biopharmawatch.com/news/TRAX/first-tracks-biotherapeutics-anb033-phase-1b-trial-data BiopharmaWatch en 2026-10-11T20:00:00.000Z First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026 https://www.biopharmawatch.com/news/BBIO/acoramidis-improves-outcomes-vs-tafamidis-attr-cm BiopharmaWatch en 2026-10-11T18:30:00.000Z Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records https://www.biopharmawatch.com/news/FRNM/freenome-new-validation-data-crc-screening-test-acg-2026 BiopharmaWatch en 2026-10-11T17:00:00.000Z Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026 https://www.biopharmawatch.com/news/BBIO/encaleret-phase-3-calibrate-trial-results BiopharmaWatch en 2026-10-11T15:42:00.000Z Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1 https://www.biopharmawatch.com/news/MRK/merck-presents-one-year-results-pivotal-phase-2b-3-brunello BiopharmaWatch en 2026-10-10T22:10:00.000Z Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026 https://www.biopharmawatch.com/news/MRK/merck-brunello-study-results-remigromig-dme BiopharmaWatch en 2026-10-10T22:10:00.000Z Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026 https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-preclinical-data-lb-102-ecnp-congress BiopharmaWatch en 2026-10-10T12:00:00.000Z LB Pharmaceuticals Presents New Preclinical Data Supporting LB-102’s Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP Congress https://www.biopharmawatch.com/news/VTVT/vtv-therapeutics-presentation-breakthrough-t1d-congress-2026 BiopharmaWatch en 2026-10-10T12:00:00.000Z vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026 https://www.biopharmawatch.com/news/MNKD/mannkind-furoscix-readyflow-hfsa-2026 BiopharmaWatch en 2026-10-10T00:00:00.000Z MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)